{"word_count": 149, "character_count": 1075}
Auteur : Rocky Swift, Christine Soares (Additional reporting by Sangmi Cha in Seoul; Editing by Elyse Tanouye and Carmel Crimmins).Production : Reuters, agence de presse mondiale et généraliste fondée en 1851 à Londres. Diffusion : site de ReutersDate : 13 mai 2020In the global hunt for coronavirus treatments, a Japanese antiviral  medicine known as Avigan has won plaudits from Prime Minister Shinzo Abe  and $128 million in government funding.  Source : Rocky Swift, Christine Soares, « A tale of two Japanese drugs in tests to fight COVID-19 », Reuters, 13/05/2020. URL : https://www.reuters.com/article/us-health-coronavirus-japan-medicine/a-tale-of-two-japanese-drugs-in-tests-to-fight-covid-19-idUSKBN22O3DC (consulté le 13/05/2020).Photo «&#160;à la une&#160;» : Tablets of Avigan (generic name : Favipiravir), a drug approved as an anti-influenza drug in Japan and developed by drug maker Toyama Chemical Co, a subsidiary of Fujifilm Holdings Co. are displayed during a photo opportunity at Fujifilm's headquarters in Tokyo October 22, 2014. © Reuters / Issei Kato 